Home/Pipeline/HIV Gene Therapy

HIV Gene Therapy

HIV

Pre-clinicalActive

Key Facts

Indication

HIV

Phase

Pre-clinical

Status

Active

Company

Nanite

About Nanite

Founded in 2019 and based in Cambridge, USA, Nanite is a private, pre-clinical biotech leveraging a proprietary AI platform called SAYER to engineer polymer nanoparticles for genetic drug delivery. The platform integrates computational design, automated synthesis, and multi-modal biological screening to rapidly identify PNPs with optimal tissue targeting, expression, and safety profiles. Nanite is initially targeting genetic diseases, with disclosed work in cystic fibrosis and an HIV gene therapy project funded by the Gates Foundation, positioning itself as a potential disruptor in the gene therapy delivery space.

View full company profile

Therapeutic Areas

Genetic Diseases Cystic Fibrosis HIV

Other HIV Drugs

Drug	Company	Phase	Status
Vaxine HIV Vaccine	Vaxine	Preclinical	Active
OraQuick® HIV Self-Test	OraSure	Commercial	FDA Approved; Marketed
Tenofovir Disoproxil Fumarate	Hetero	Commercial	Active
NanoDDI	Continuity Biosciences	Pre-clinical	Active
RGFields for HIV	Anapole Technologies	Clinical (phase unspecified)	Active
HIV mAb Program	Adnexus	Pre-clinical	Active
Undisclosed Program	EnnoDC	Phase 1	Active
O2-16 Series	OyaGen	Preclinical	Active
SBX 2048	Stramsen Biotech	Early-stage Clinical	Active
ALF Platform	Senzo	Pre-clinical	Active
Gilead HIV Franchise	Royalty Pharma	Marketed	Active
ANKTIVA-based regimens	ImmunityBio	Phase 1/2	Active